MayTech Global Investments LLC Increases Position in DexCom, Inc. (NASDAQ:DXCM)

MayTech Global Investments LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 14.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,576 shares of the medical device company’s stock after purchasing an additional 17,194 shares during the period. DexCom comprises approximately 3.4% of MayTech Global Investments LLC’s portfolio, making the stock its 14th largest position. MayTech Global Investments LLC’s holdings in DexCom were worth $17,166,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of DXCM. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of DexCom by 141,272.2% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 47,321,524 shares of the medical device company’s stock valued at $6,081,289,000 after acquiring an additional 47,288,051 shares during the last quarter. Norges Bank purchased a new position in DexCom in the fourth quarter valued at approximately $421,378,000. 1832 Asset Management L.P. acquired a new stake in DexCom during the fourth quarter worth approximately $151,538,000. Clearbridge Investments LLC lifted its position in shares of DexCom by 304.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock worth $674,329,000 after buying an additional 992,049 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in shares of DexCom by 287.6% in the 1st quarter. Thrivent Financial for Lutherans now owns 846,632 shares of the medical device company’s stock valued at $98,362,000 after buying an additional 628,201 shares during the last quarter. Institutional investors and hedge funds own 93.88% of the company’s stock.

Insider Buying and Selling at DexCom

In related news, EVP Barry J. Regan sold 2,019 shares of DexCom stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $95.22, for a total transaction of $192,249.18. Following the completion of the transaction, the executive vice president now directly owns 64,250 shares in the company, valued at approximately $6,117,885. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, Director Bridgette P. Heller sold 600 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $106.56, for a total transaction of $63,936.00. Following the completion of the sale, the director now owns 23,731 shares of the company’s stock, valued at $2,528,775.36. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Barry J. Regan sold 2,019 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $95.22, for a total transaction of $192,249.18. Following the completion of the sale, the executive vice president now directly owns 64,250 shares of the company’s stock, valued at approximately $6,117,885. The disclosure for this sale can be found here. Insiders have sold 8,752 shares of company stock valued at $850,297 over the last quarter. Corporate insiders own 0.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DXCM shares. Robert W. Baird reduced their price target on shares of DexCom from $153.00 to $130.00 and set an “outperform” rating for the company in a research report on Monday, August 21st. Stifel Nicolaus cut their price target on DexCom from $155.00 to $145.00 and set a “buy” rating on the stock in a research report on Tuesday, October 10th. StockNews.com assumed coverage on shares of DexCom in a research report on Thursday, October 5th. They set a “hold” rating on the stock. Leerink Partnrs restated an “outperform” rating on shares of DexCom in a research report on Monday, October 16th. Finally, Raymond James decreased their price target on shares of DexCom from $154.00 to $131.00 and set a “strong-buy” rating for the company in a research note on Friday, September 15th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $130.93.

DexCom Price Performance

Shares of DexCom stock traded up $2.21 during trading on Monday, reaching $107.18. The company’s stock had a trading volume of 815,628 shares, compared to its average volume of 3,363,744. The company has a quick ratio of 2.50, a current ratio of 2.80 and a debt-to-equity ratio of 1.07. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $139.55. The company has a market capitalization of $41.41 billion, a P/E ratio of 115.35, a price-to-earnings-growth ratio of 2.13 and a beta of 1.13. The business has a 50 day moving average price of $91.03 and a 200-day moving average price of $109.77.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 26th. The medical device company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.16. The business had revenue of $975.00 million for the quarter, compared to analysts’ expectations of $939.64 million. DexCom had a return on equity of 25.05% and a net margin of 11.08%. The company’s revenue was up 26.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.28 EPS. As a group, sell-side analysts anticipate that DexCom, Inc. will post 1.43 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.